not tagged
not tagged
[]
cart-ddbcma, an investigational car t-cell therapy which uses a novel synthetic binding domain referred to as a d-domain to target bcma, has demonstrated clinical activity in a phase 1 study for patients with r/r mm. #esmo2022 read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.